Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697019 | Brachytherapy | 2017 | 6 Pages |
Abstract
A majority of respondents were unaware of Co-60 as a commercially available HDR source. This investigation was novel in directly assessing decision makers to establish WTP for shielding costs that source change to Co-60 may require. These results will be used to establish WTP threshold for future cost-benefit analysis.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Raymond Mailhot Vega, Wesley Talcott, Omar Ishaq, Patrice Cohen, Christina J. Small, Tamara Duckworth, Gustavo Sarria Bardales, Carmen A. Perez, Peter B. Schiff, William Jr., Matthew M. Harkenrider,